Internal Medicine, Hematology · Tampa, FL
NPI
1942266929
Since 2006
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
12902 Usf Magnolia Dr
Tampa, FL, 33612
Phone (813) 745-4673
Groups this clinician bills Medicare through
Medicare paid, 2024
$27K
354 services
Medicare patients, 2024
180
Average age 75
Drug cost, 2024
$2.8M
291 prescriptions
Company payments, 2025
$184K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rami S Komrokji was code 99214 (office e&m - established), 131 times for 99 patients. In total Rami S Komrokji billed 354 services in 11 codes, and Medicare paid $27K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 131 | 99 | $67.25 | $8,810 |
| 99214 Office E&M - Established | Office | 63 | 50 | $100.59 | $6,337 |
| 99205 Office E&M - New | Facility | 42 | 42 | $141.36 | $5,937 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 28 | 24 | $12.97 | $363 |
| 99213 Office E&M - Established | Facility | 16 | 15 | $52.12 | $834 |
| 99213 Office E&M - Established | Office | 14 | 14 | $71.24 | $997 |
By year: 2022 $34K for 415 services; 2023 $31K for 374 services; 2024 $27K for 354 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rami S Komrokji prescribed most often to Medicare patients was Allopurinol, with 20 prescriptions and refills. In total Rami S Komrokji wrote 291 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Allopurinol Generic | 20 | 38 | 12 | $86.42 |
| Ojjaara Momelotinib Dihydrochloride | 19 | 19 | Under 11 | $518K |
| Inqovi Decitabine/Cedazuridine | 19 | 19 | 11 | $151K |
| Oxycodone Hcl Generic | 16 | 16 | Under 11 | $116 |
| Hydroxyurea Generic | 14 | 30 | Under 11 | $371 |
| Vanflyta Quizartinib Dihydrochloride | 13 | 13 | Under 11 | $390K |
| Promacta Eltrombopag Olamine | 13 | 13 | Under 11 | $198K |
| Xospata Gilteritinib Fumarate | 13 | 13 | Under 11 | $245K |
| Venclexta Venetoclax | 13 | 13 | Under 11 | $45K |
| Vonjo Pacritinib Citrate | 11 | 11 | Under 11 | $282K |
Brand drugs: 158 claims; generic drugs: 133 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rami S Komrokji $184K ($181K in general payments such as food, travel and fees and $2,861 for research) from 16 companies. The largest payer was PharmaEssentia USA Corporation with $46K.
| Company | Payments | Amount |
|---|---|---|
| PharmaEssentia USA Corporation 6446.TW | 25 | $46K |
| Sobi, Inc SOBI.ST | 19 | $33K |
| Syndax Pharmaceuticals, Inc. SNDX | 14 | $26K |
| Geron Corporation GERN | 20 | $22K |
| Hikma Pharmaceuticals USA HIK.L | 9 | $12K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 23 | $11K |
| Rigel Pharmaceuticals, Inc. RIGL | 14 | $11K |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $8,118 |
| Celgene Corporation BMY | 4 | $7,369 |
| Servier Pharmaceuticals LLC | 3 | $5,539 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.